|Bid||1.0200 x 2900|
|Ask||1.0300 x 1200|
|Day's Range||1.0246 - 1.0600|
|52 Week Range||0.9100 - 10.3800|
|Beta (3Y Monthly)||-1.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
I've been keeping an eye on Proteostasis Therapeutics, Inc. (NASDAQ:PTI) because I'm attracted to its fundamentals...
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
Proteostasis (PTI) delivered earnings and revenue surprises of 34.88% and 525.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Boston-based company said it had a loss of 28 cents. The biopharmaceutical company posted revenue of $5 million in the period. In the final minutes of trading on Wednesday, the ...
During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Proteostasis Therapeutics, Inc.'s (NASDAQ:PTI): Proteostasis Therapeutics, Inc., a clinical sta...
Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! As an investor, mistakes are inevitable. But really big lossesRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...
A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's treatment.
What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.
Shares of Proteostasis Therapeutics Inc. plunged 58% on heavy volume in morning trade Monday, enough to pace all decliners trading on major U.S. exchanges, after biopharmaceutical company announced results from a phase 1 study of its cystic fibrosis (CF) treatment. Trading volume ballooned to 7.6 million shares, compared with the full-day average of 1.2 million shares. The company said the increase in ppFEV1 at day 14 of a statistically significant 5 percentage points versus baseline was observed in the 600 milligram PTI-801 cohort. Analyst Geoffrey Porges at SVB Leerink said the results CF did not meet the efficacy of Vertex Pharmaceuticals Inc.'s medicines, as that 5% was below the 13%-14% hurdle established by Vertex. Porges believes the results of Proteostasis' trial removes the final "long-shot competitor" to Vertex's CF portfolio. Vertex shares gained 1.0% in morning trade. Proteostasis's stock has lost 66.3% over the past 12 months, while Vertex shares have rallied 13.8% and the S&P 500 has gained 7.8%.
Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of ProteostasisRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 20) • XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech ...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
The Waltham startup is taking on the market giant Vertex Pharmaceuticals by developing an injection that targets the 10 percent of patients that Vertex and others haven't touched.
Ryan McQueeney discusses concerns about slowing economic growth in China and a major court ruling affecting healthcare stocks. He also highlights trending stocks Proteostasis Therapeutics and New Age Beverages. Later, he previews earnings from Red Hat, Oracle, and Micron.
The Boston, Mass.-based company said that it has reached an exclusive license agreement to offer the rights for a Genentech product–the company is part of the Roche Group. The product in question are therapeutic small molecule modulators designed to treat some form of cystic fibrosis with an undisclosed target to be integrated from the Proteostasis network. The deal does not include the cystic fibrosis transmembrane conductance regulator (CFTR) modulators and it has no connection to PTI’s investigational medicines or any of its other ongoing research programs linked to the ailment. “We are thrilled to enter into this agreement with Genentech, an industry leader with a proven record of success in small molecule research and development,” said Meenu Chhabra, who is the President and CEO of Proteostasis Therapeutics.
Proteostasis Therapeutics develops therapies for the treatment of cystic fibrosis, or CF, and other diseases and struck an agreement with Genentech for the rights to a potential therapeutic small molecule modulators of an undisclosed target within the Proteostasis Network. In exchange for the rights, Proteostasis will receive upfront milestone payments of more than $100 million from Genentech and tiered royalties on sales of future medicines from the license agreement. Proteostasis Therapeutics' new licensing agreement validates its network potential and could be seen as a sign that future agreements will arise, Cantor Fitzgerald's Elemer Piros said in a research report.
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.